Drugs / BL-M11D1
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06714591 | Dec 2024 → Dec 2026 expected | acute myeloid leukemia | SystImmune Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05924750 | Aug 2023 → Dec 2026 expected | acute myeloid leukemia | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07591168 | May 2026 → Dec 2028 expected | myelodysplastic syndrome | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07255872 | Mar 2026 → Dec 2027 expected | acute myeloid leukemia | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-M11D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06714591 ↗ |
| Route | Intravenous | “Administration by intravenous infusion” NCT05924750 ↗ |